4 Weeks Glecaprevir/Pibrentasvir Hepatitis C Treatment
Here’s a breakdown of the key information from the provided text,focusing on the PURGE-C study and its limitations:
PURGE-C Study Summary:
* Design: Phase 2,open-label,single-arm trial (US & Brazil)
* Participants: 45 adults with early HCV infection (first-time or documented reinfection). Half were also living with HIV (PWH) and on stable antiretroviral therapy.
* Intervention: Four weeks of glecaprevir/pibrentasvir (G/P) at 300mg/120mg once daily.
* Primary Outcome: Sustained Virologic Response at 12 weeks (SVR12) – meaning the virus was undetectable 12 weeks after treatment ended.
* Results: 84% (38/45) of patients achieved SVR12. 83% of PWH achieved SVR12. 75% of PWID achieved SVR12.
* Adverse Events (AEs): 73% experienced moderate or higher AEs,mostly mild elevations in creatinine or liver markers,or unrelated infections. No one stopped treatment due to AEs.
Limitations:
* Small Sample Size: The study enrolled only 45 participants.
* Limited Depiction of PWID: Only 27% (12/45) of participants were people who inject drugs (PWID).
* Demographics: Predominantly white (51%), Hispanic (31%), and Black (27%).only one participant was female.
* Generalizability: The authors acknowledge the results may not be broadly applicable due to the small sample size and limited PWID representation.
Key Takeaways:
* A four-week G/P regimen shows promise for treating early HCV infection.
* early treatment may improve outcomes.
* Larger, more diverse trials are needed before this shorter treatment duration can be widely adopted.